Vectibix (panitumumab)

P3, N=160, Active, not recruiting, Amgen | Trial completion date: Jan 2026 --> May 2026

These findings support the use of anti-EGFR rechallenge strategy aslater-line treatment when tumor shrinkage is a clinical priority. Further evidence from prospective trials is required.

P2, N=16, Active, not recruiting, Nicholas DeVito, MD | Recruiting --> Active, not recruiting

P1, N=434, Recruiting, Amgen | Trial completion date: Oct 2030 --> Apr 2031 | Trial primary completion date: Oct 2027 --> Apr 2028

P2, N=214, Active, not recruiting, Gruppo Oncologico del Nord-Ovest | Trial completion date: Dec 2025 --> Mar 2026

P2, N=14, Recruiting, Amgen | Not yet recruiting --> Recruiting

Monotherapy with KRAS G12C inhibitors demonstrated an objective response rate of 23%, while combination therapies with agents such as cetuximab and panitumumab showed a higher response rate of 43%. High heterogeneity across studies suggests variability due to small sample sizes and early-phase trial designs. While preliminary data are promising, further large-scale phase III trials are essential to establish these inhibitors as a standard treatment for KRAS G12C-mutant CRC.

Ion Chiricuta" between 2015 and 2024 with first-line FOLFOX/FOLFIRI plus panitumumab...In multivariate analysis, only bNLR remained independently associated with PFS. These results suggest that both baseline and dynamic NLR may serve as low-cost prognostic biomarkers in mCRC patients treated with anti-EGFR therapy.

After receiving capecitabine monotherapy as first-line therapy, S-1 plus irinotecan plus bevacizumab therapy as second-line, trifluridine/tipiracil (FTD/TPI) monotherapy as third-line, and regorafenib monotherapy as fourth-line therapy, the patient received panitumumab monotherapy as fifth-line therapy...After receiving mFOLFOX6 plus panitumumab therapy as first-line therapy, FOLFIRI plus bevacizumab as second-line, he underwent conversion surgery...As third-line therapy, he received pembrolizumab monotherapy...We encountered two patients with mCRC and EGFR gene amplification who responded to panitumumab monotherapy. EGFR gene amplification may be a potential biomarker for anti-EGFR antibodies, regardless of RAS status.

P1, N=5, Terminated, Rutgers, The State University of New Jersey | Active, not recruiting --> Terminated; slow accrual

The clinical development of this combination strategy was discontinued, as brigatinib treatment was not feasible in patients with advanced EGFR-mutated NSCLC resistant to osimertinib.

P2, N=59, Active, not recruiting, M.D. Anderson Cancer Center | Trial completion date: Jan 2026 --> Jan 2027 | Trial primary completion date: Jan 2026 --> Jan 2027